Strategic Expansion and Clinical Potential of Werewolf Therapeutics’ PREDATOR Platform Boosts Buy Rating

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Werewolf Therapeutics (HOWL – Research Report) on May 9 and set a price target of $12.00.

Daina Graybosch’s rating is based on Werewolf Therapeutics’ strategic expansion of their PREDATOR masking platform, which now includes CD3 T-cell engagers (TCEs) in addition to cytokines. This expansion is noteworthy due to the strong clinical validation and significant industry interest in TCEs. Werewolf’s approach is supported by their existing clinical programs, particularly WTX-124 and WTX-330, which demonstrate effective tumor-conditional masking.
Although the TCE platform is still in early development and may not immediately impact the stock’s value, Graybosch anticipates that as Werewolf’s preclinical TCE candidates progress and achieve clinical success, investor interest will grow. Additionally, upcoming clinical updates, such as the Phase 1b dose expansion data for WTX-124 expected in the second half of 2025, could further validate their technology and potentially reinvigorate interest in the stock. The potential for IL-2 to play a role in immuno-oncology treatments, combined with Werewolf’s innovative approach, supports the Buy rating.

In another report released on May 9, Wedbush also maintained a Buy rating on the stock with a $6.00 price target.